Zimulti

Generic name: Rimonabant

Usage of Zimulti

  • Zimulti (rimonabant) was the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).
  • Zimulti was studied in the treatment of obesity, as an aid for smoking cessation, and related conditions.

    • Zimulti side effects

  • Side effects in the trial on Zimulti in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.
  • Clinical studies found that 26 percent of people taking Zimulti reported psychiatric symptoms, including anxiety, insomnia, panic attacks as well as increases in aggression and agitation compared to patients given a placebo.
  • Zimulti has also been shown to cause increased suicidal tendencies and other depressive symptoms.8

    • References:

  • Personal Communication. Sanofi-Aventis Medical Information Department. Rimonabant availability. September 12, 2011
  • Pagotto U. Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005; 365: 1363-64.
  • Van Gaal LF, Rissanen, AM, Scheen AJ, Ziegler O, Rössner S for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-97.
  • Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
  • Després, J.P. et al. Effect of Rimonabant on Body Weight and the Metabolic Syndrome in Overweight Patients. New England Journal of Medicine, November, 16, 2005.
  • Van Gaal L, et al. Effects Of The Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction And Cardiovascular Risk Factors In Overweight Patients: 1-Year Experience From The RIO-Europe Study. The Lancet. 365;1389-1397.
  • Zimulti Summary of Product Characteristics
  • Testimony Before FDA Advisory Committee Meeting on Rimonabant (HRG Publication #1815), Testimony of Sidney Wolfe, M.D., Ben Wolpaw and Elizabeth Barbehenn Ph.D. Health Research Group of Public Citizen. FDA Endocrine Metabolic Drugs Advisory Committee Meeting on Rimonabant: June 13, 2007

    • Sources:

    Rimonabant Accepted for Filing By the FDA June 23, 2005

    Sanofi-aventis Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation February 17, 2006

    FDA Advisory Committee Did Not Recommend Approval of Rimonabant (Zimulti) for Use in Obese and Overweight Patients With Associated Risk Factors June 13, 2007

    Weight Loss Drug Zimulti (rimonabant) Can Cause Serious Physical and Psychological Harm and Birth Defects, Public Citizen Tells FDA June 13, 2007

    Sanofi-Aventis to Discontinue Rimonabant Trials for All Indications November 6, 2008

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords